Compare Incyte Corporation (INCY) vs SYSCO Corporation (SYY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs SYSCO Corporation — how do they compare? Incyte Corporation trades at $118.02 (market cap $23.11B), while SYSCO Corporation trades at $80.41 (market cap $38.63B). The key difference: SYSCO Corporation is the larger of the two by market cap, and SYSCO Corporation pays a 2.72% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | SYY | |
|---|---|---|
Market Cap | $23.11B | $38.63B |
Sector | Health | Consumer Staples |
52-Week High | $118.52 | $91.16 |
52-Week Low | $67.38 | $69.30 |
Enterprise Value | $19.13B | $52.11B |
Dividend Yield | — | 2.72% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $115.66, down 1.36% on the day, with a bullish technical signal from moving averages and strong fundamental performance including a 25.02% net income margin for 2025. Recent positive news includes regulatory approvals for Opzelura in Europe and the acquisition of Vega Therapeutics, expanding its hematology portfolio. Revenue grew to $5.14 billion in 2025, with earnings beating expectations in two of the last three quarters.
The outlook remains positive given robust profitability, pipeline advancements, and a majority analyst buy rating, though risks include competitive pressures and reliance on key drug performance. The stock's current price is slightly above the consensus target of $112.78, suggesting near-term consolidation potential amid longer-term growth catalysts.
SYY trades at $81.02, down 0.82% on the day, with a neutral technical signal and support at $81. The company reported $81.37B in revenue for 2025 with a net margin of 2.08%, and upcoming Q4 2026 earnings on August 4 are expected at $1.51 EPS. Positive cash flow trends and a dividend of $0.55 payable July 24 provide stability, while analyst consensus is bullish with a $84.75 price target.
Outlook is cautiously optimistic given analyst buy ratings (60%) and steady revenue growth, but risks include thin profit margins and high debt levels. The stock offers value with a P/S of 0.47, though near-term performance hinges on earnings results and macroeconomic conditions affecting the food distribution sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About SYSCO Corporation
Sysco is the largest U.S. food-service distributor, boasting 17% market share of the highly fragmented food-service distribution industry. Sysco distributes over 400,000 food and nonfood products to restaurants (63% of revenue), healthcare facilities (8%), education and government buildings (8%), travel and leisure (7%), and other locations (14%) where individuals consume away-from-home meals. In fiscal 2022, 82% of the firm's revenue was U.S.-based, with 7% from Canada, 4% from the U.K., 2% from France, and 4% other.
Read more on SYY →
